Europe's Hidden HIV Crisis: Over Half of Diagnoses Come Too Late

On Thursday, health authorities across Europe sounded an alarm about a crisis unfolding largely out of public view. The European Centre for Disease Prevention and Control and the World Health Organization's regional office released a surveillance report documenting what they called a "hidden" HIV emergency: more than half the people diagnosed with the virus in Europe are discovering their infection only after their immune systems have already been severely damaged.

The numbers tell the story. In 2024, the WHO European Region recorded 105,922 new HIV diagnoses. Of these, 54 percent arrived too late—meaning the person's CD4 cell count, a key measure of immune function, had already fallen below 350 cells per cubic millimeter. At that threshold, the body's defenses are already compromised. In the 30 countries of the European Union and European Economic Area specifically, 24,164 diagnoses were reported, with 48 percent classified as late. That's roughly one in two people learning they have HIV only after the virus has had years to weaken them.

The consequences ripple outward. A late diagnosis means antiretroviral drugs, which are highly effective when started early, deliver fewer benefits. The risk of developing AIDS climbs. Death becomes more likely. And because people with uncontrolled HIV transmit the virus more readily, late diagnosis becomes a vector for continued spread. This matters not as an abstract public health metric but as a barrier to the world's stated goal of ending AIDS as a public health threat by 2030. Europe, with its wealth and medical infrastructure, is falling short.

The root causes are not mysterious. Testing remains fragmented and inconsistent across the region. Many people never get tested at all, so they never know their status. Those who might seek testing often face a wall of stigma and discrimination—the kind that makes someone hesitate to walk into a clinic, that makes a doctor's office feel unsafe, that turns a simple medical question into a social risk. Hans Henri P. Kluge, the WHO's regional director for Europe, named this plainly: "We are not doing enough to remove the deadly barriers of stigma and discrimination that prevent people from seeking out a simple test."

Pamela Rendi-Wagner, director of the ECDC, framed the challenge as one of strategy and will. "Nearly half of all diagnoses are made late," she said of the EU and EEA countries. "We must urgently innovate our testing strategies, embrace community-based testing and self-testing, and ensure rapid linkage to care." The implication was clear: the tools exist. What's missing is the commitment to deploy them widely and the cultural shift to make testing routine rather than stigmatized.

The agencies are calling for a fundamental reorientation. Testing needs to become normalized—offered in primary care settings, workplaces, and community spaces, not confined to specialized clinics. Self-testing kits should be widely available and accessible. Once someone tests positive, the pathway to treatment must be swift and certain. And the stigma that keeps people away from testing in the first place must be actively dismantled through public messaging and policy change.

What makes this a "hidden" crisis is that it's not a sudden outbreak or a visible emergency. It's a slow accumulation of missed opportunities, each one a person who could have started treatment years earlier, each one a transmission that might have been prevented. The data arrived quietly on a Thursday in late November. Whether Europe responds with the urgency the moment demands remains to be seen.